|
|
|
|
||
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal It seems that NKTR-214 and Nivo combo cannot provide stronger benefits as compared to current IO-TKI combos in RCC https://www.biospace.com/article/releases/nektar-therapeutics-announces-publication-of-results-from-phase-1-dose-escalation-study-for-bempegaldesleukin-plus-nivolumab-in-cancer-discovery-journal/ full paper: https://cancerdiscovery.aacrjournals.org/content/candisc/early/2020/05/20/2159-8290.CD-19-1510.full.pdf |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
24678 | Re: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal | Pacific | 2 | 5/22/2020 7:56:02 PM |